Development of combinatorial antibody therapies for diffuse large B cell lymphoma

Diffuse large B-cell lymphoma (DLBCL), the most common form of lymphoma, is typically treated with chemotherapy combined with the immunotherapy rituximab, an antibody targeting the B cell receptor, CD20. Despite the success of this treatment regimen, approximately a third of DLBCL patients experienc...

Descripción completa

Detalles Bibliográficos
Autores principales: Geanes, Eric S., Krepel, Stacey A., McLennan, Rebecca, Pierce, Stephen, Khanal, Santosh, Bradley, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637670/
https://www.ncbi.nlm.nih.gov/pubmed/36353222
http://dx.doi.org/10.3389/fmed.2022.1034594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637670/
https://www.ncbi.nlm.nih.gov/pubmed/36353222
http://dx.doi.org/10.3389/fmed.2022.1034594

Ejemplares similares